Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis
For patients with COVID-19, a multinational registry analysis reported the following for patients given different antimalarial and macrolide therapies between 12/20/19 and 4/14/20:
-
Hazard ratios for in-hospital mortality
-
Hazard ratios for ventricular arrhythmia
0
1
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19
Hydroxychloroquine as Prophylactic Treatment for COVID-19
Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial
Observational Study of Hydroxychloroquine in Hospitalized Patients with COVID-19
Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State
Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis
Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized-Controlled Trial
Learn After
Hazard ratios for in-hospital mortality among COVID-19 patients given different antimalarial and macrolide therapies from multinational registry of patients hospitalized between 12/20/19 and 4/14/20
Hazard ratios for ventricular arrhythmia among COVID-19 patients given different antimalarial and macrolide therapies from multinational registry of patients hospitalized between 12/20/19 and 4/14/20